中华预防医学杂志
中華預防醫學雜誌
중화예방의학잡지
CHINESE JOURNAL OF
2015年
2期
184-188
,共5页
罗莉%邢薇佳%廖巧红%余宏杰
囉莉%邢薇佳%廖巧紅%餘宏傑
라리%형미가%료교홍%여굉걸
肠道病毒属%手足口病%血清流行病学研究%柯萨奇病毒A16
腸道病毒屬%手足口病%血清流行病學研究%柯薩奇病毒A16
장도병독속%수족구병%혈청류행병학연구%가살기병독A16
Enterovirus%Hand,foot and mouth disease%Seroepidemiology studies%Coxsackievirus A16
手足口病由肠道病毒感染引起,以肠道病毒71型(EV-A71)和柯萨奇病毒A16型(CV-A16)最为常见,患者和隐性感染者均为传染源.通过血清学调查,可以掌握人群中EV-A71和CV-A16抗体水平,以及不同年龄段人群的易感性和免疫水平动态变化.通过对EV-A71和CV-A16血清流行病学科研文献进行检索和回顾性研究,系统分析了不同年龄人群中的EV-A71和CV-A16抗体水平,探讨人群易感性、免疫水平动态变化及人群感染状况.研究发现新生儿EV-A71和CV-A16中和抗体水平与母亲密切相关,接近成年人水平;随着母传抗体的自然衰减,在1年之内会迅速下降至最低水平;1~4岁时迅速升高,5岁之后将达到一个稳定水平.接种疫苗是预防手足口病感染的有效措施,现有研究提示6~12月龄为手足口病疫苗接种的最佳年龄段.
手足口病由腸道病毒感染引起,以腸道病毒71型(EV-A71)和柯薩奇病毒A16型(CV-A16)最為常見,患者和隱性感染者均為傳染源.通過血清學調查,可以掌握人群中EV-A71和CV-A16抗體水平,以及不同年齡段人群的易感性和免疫水平動態變化.通過對EV-A71和CV-A16血清流行病學科研文獻進行檢索和迴顧性研究,繫統分析瞭不同年齡人群中的EV-A71和CV-A16抗體水平,探討人群易感性、免疫水平動態變化及人群感染狀況.研究髮現新生兒EV-A71和CV-A16中和抗體水平與母親密切相關,接近成年人水平;隨著母傳抗體的自然衰減,在1年之內會迅速下降至最低水平;1~4歲時迅速升高,5歲之後將達到一箇穩定水平.接種疫苗是預防手足口病感染的有效措施,現有研究提示6~12月齡為手足口病疫苗接種的最佳年齡段.
수족구병유장도병독감염인기,이장도병독71형(EV-A71)화가살기병독A16형(CV-A16)최위상견,환자화은성감염자균위전염원.통과혈청학조사,가이장악인군중EV-A71화CV-A16항체수평,이급불동년령단인군적역감성화면역수평동태변화.통과대EV-A71화CV-A16혈청류행병학과연문헌진행검색화회고성연구,계통분석료불동년령인군중적EV-A71화CV-A16항체수평,탐토인군역감성、면역수평동태변화급인군감염상황.연구발현신생인EV-A71화CV-A16중화항체수평여모친밀절상관,접근성년인수평;수착모전항체적자연쇠감,재1년지내회신속하강지최저수평;1~4세시신속승고,5세지후장체도일개은정수평.접충역묘시예방수족구병감염적유효조시,현유연구제시6~12월령위수족구병역묘접충적최가년령단.
Most common causative agents for hand,foot and mouth disease (HFMD) are enterovirus 71 (EV-A71) and coxsackievirus A16 (CV-A16).The symptomatic and asymptomatic cases could transmit the disease in population.Many sero-epidemiological surveys were launched to estimate the sero-incidence of EV-A71 and CV-A16 enterovirus,the susceptibility of different sub-population,and to observe the dynamics of neutralizing antibody.A literature search of sero-epidemiological study focused on EV-A71 or CV-A16 was conducted via PubMed and China Hospital Knowledge Database.Based on the 20 selected studies,the different age groups' antibody level,the susceptibility,the dynamics of antibody and sero-incidence of EV-A71 or CV-A16 were analyzed.From our results,the antibody level against EV-A71 or CV-A16 in neonates was associated with their mothers,which was similar with that of adults.The antibody level against EV-A71 or CV-A16 in neonates dropped to lowest level at one years-old,and started to dramatically increase until four years-old,and reached a plateau at five years-old.In conclusion,the infants aged 6-12 months were the priority group to receive vaccination when the EV-A71 vaccine is licensed in the future.